AUTODECRA 1
AUTODECRA 1
Autologous Tolerogenic Dendritic Cells for Rheumatoid and Inflammatory Arthritis
• Study stage: Closed
• Sponsor: The Newcastle upon Tyne Hospitals NHS Foundation Trust
• Funder: Arthritis Research UK
• Therapeutic area: Musculoskeletal
• Type of study: ATIMP
Aim: To assess safety of intra-articular TolDC in patients with RA and other chronic inflammatory arthritis
Primary Outcome: The proportion of patients experiencing AEs and SAEs following the intra-articular administration of TolDC.
• Population: Adults
• Clinical Phase: I
• Design: Randomised Control Trial (RCT)
• Setting: Secondary Care
• Planned Sample Size: 12